SEC Filing Summary: Pieris Pharmaceuticals, Inc. (PIRS)
Business Context and Reporting Period
This Form 8-K was filed on January 24, 2022, by Pieris Pharmaceuticals, Inc. The report serves to disclose the presentation of unaudited financial results for the fiscal year ended December 31, 2021, via an Investor Presentation furnished as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached Investor Presentation (Exhibit 99.1), which is not included in the provided text.
Material Changes
The filing does not detail specific material changes versus prior periods. It solely references the announcement of the full-year 2021 results.
Guidance, Outlook, and Risks
Management commentary, guidance, and risk factors are referenced as being part of the January 2022 Investor Presentation. The filing explicitly states that the information in Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (January 2022 Investor Presentation) for actual financial figures.
- Verify the unaudited status of the reported fiscal year 2021 results.
- Confirm the company's status as an emerging growth company (indicated as not checked in the form).
- Note that the disclosure is made under Regulation FD and Item 2.02.